In March, the FDA cleared several new indications: Tremfya for Crohn’s disease, Amvuttra to reduce heart-related death in ATTR-CM, and Imfinzi to treat muscle invasive bladder cancer. GSK’s first-in-class Blujepa is approved for uncomplicated UTIs, Celltrion’s Omlyclo is a new interchangeable biosimilar to Xolair, and Arbli is the first losartan, shelf-stable oral suspension. Other approvals include: Encelto for Macular Telangiectasia Type 2, Vykat XR for hyperphagia in Prader-Willi Syndrome and Sanofi’s Qfitlia for hemophilia.